profile

Jeremy London, M.D.

5 New Studies You Should Know


5 New Studies You Should Know

Disclaimer: Not Medical Advice. Opinions are my own.

Was this newsletter forwarded to you? Subscribe here​

In partnership with Rho Nutrition​
​Most Bioavailable Supplements Available​


We want you to stay well informed and on top of current data.

We're starting something new: whenever relevant, actionable research is released, we'll share it with you.

You'll receive the study itself, what it measured, what it found, what it didn't fully answer, and what it means for you.


5 New Studies You Should Know

1. A brisk everyday walking pace was linked to a lower risk of death

The study: Clinical Walking Speed, Free-Living Walking Cadence, and All-Cause Mortality, JAMA Network Open, October 2026

What they measured: 4,067 older adults in the UK's long-running Whitehall II study (average age 69) had their walking measured two ways. First, a short timed walk in a clinic. Second, a wrist tracker worn for 9 days that recorded their cadence: how many steps per minute they took while walking in everyday life. Researchers then followed them for about 12 years and tracked deaths from any cause.

What they found: Pace mattered, no matter how it was measured. After accounting for age, health conditions, smoking, and other lifestyle factors, walking faster than the group average was linked to a lower risk of death, and the risk kept falling as pace increased:

  • 23% lower for a faster walk in the clinic test
  • 17% lower for a brisker typical everyday walking cadence
  • 18% lower for a brisker pace during their fastest stretches of walking

The tracker data predicted risk about as well as the clinic test, which means the pace you walk in everyday life carries real information about your health.

What it didn't prove: This is an observational study, so it shows a link, not cause and effect. People who walk faster may already be healthier, and some of the benefit may reflect that rather than the walking itself. Three-quarters of participants were men, mostly office workers in London, so the results may not apply equally to everyone. And the study tracked pace, not whether people who deliberately sped up lived longer.

The takeaway: When you walk, walk with purpose; a brisk everyday pace is one of the simplest habits linked to a longer life.

2. Lifting weights on tirzepatide kept more muscle and made people stronger

The study: Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity, Nature Medicine, November 9, 2026

What they measured: 120 adults with overweight or obesity all took tirzepatide for 40 weeks. Half were randomly assigned to supervised resistance training three times a week; the other half kept their usual routine. Researchers measured fat, lean mass, and strength.

What they found: Both groups lost almost exactly the same weight, about 22 kg (roughly 50 lb). But the lifting group lost 1.1 kg less lean mass: 3.6 kg vs 4.7 kg. Strength moved in opposite directions. Without training, people got weaker on every lift. With training, they got stronger: lat pulldown went up about 8.6 kg vs. down 4.4 kg. People showed up for 91% of their sessions.

What it didn't prove: "Lean mass" on a scan isn't purely muscle, and the study didn't measure falls, fractures, or long-term function. It was a small study that ran for only 40 weeks, and the exercise was supervised, which is easier to stick with than training on your own.

The takeaway: If you're on a GLP-1, pair it with strength training at least three times a week. It significantly reduces muscle loss.

3. Even light drinking raised the risk of death once a classic bias was removed

The study: Alcohol consumption and mortality after mitigating sick-quitter bias: a 19-year nationwide cohort study of Korean adults, Addiction, November 9, 2026

What they measured: Researchers followed 1.1 million Korean adults for a median of 19 years and tracked deaths from any cause, from cancer, and from alcohol-related disease. The key design choice: they tried to strip out "sick-quitter" bias. That's the problem where non-drinkers look unhealthy because many of them quit because they were sick, which makes light drinkers look healthy by comparison. To account for this, they excluded people with major illness, people who had recently cut back, and people diagnosed with cancer in the first year. Then they compared everyone to occasional drinkers instead of non-drinkers.

What they found: Risk climbed steadily with every step up in drinking. Compared with occasional drinkers, risk of death from any cause was:

  • 15% higher for light drinkers
  • 33% higher for moderate drinkers
  • 95% higher for very heavy drinkers

Cancer deaths followed the same pattern, with light drinkers at 10% higher risk. Deaths from alcohol-related disease nearly doubled even at light drinking.

What it didn't prove: Drinking was self-reported, and this is an observational study, so it shows a strong pattern rather than proof of cause. The researchers couldn't separate lifelong non-drinkers from former drinkers, so they used occasional drinkers as the comparison group. And it's a Korean population, so the results may not carry over to people with other genetics, diets, and drinking patterns.

The takeaway: No amount of regular drinking protects your health; when it comes to alcohol, less is better.

4. After a stroke, aiming for a systolic blood pressure (top number) under 120 cut major heart and stroke events by 21%

The study: Intensive Blood-Pressure Control in Patients with Previous Ischemic Stroke (OPTIMAL-STROKE), New England Journal of Medicine, November 7, 2026

What they measured: 4,368 people with high blood pressure who'd had an ischemic stroke or a TIA ("mini-stroke") were randomly assigned to one of two targets for the top number (systolic pressure): under 120 or under 140. They were followed for a median of 3.9 years for cardiovascular death, heart attack, stroke, and hospitalization for unstable angina or heart failure.

What they found: The lower-target group averaged 122 mm Hg; the standard group averaged 135 mm Hg. Major events occurred in 10.9% of the lower-target group vs 13.5% of the standard group, a 21% lower risk. Overall serious side effects were similar between the two groups.

What it didn't prove: The trial also wasn't blinded. Everyone knew which target they were assigned, which can influence how patients and doctors behave. And with a median follow-up of just under 4 years, it can't tell us whether the benefit grows or fades over a longer stretch.

The takeaway: If you've had a stroke or TIA, ask your doctor about aiming for a top number around 120, with regular kidney checks along the way.

5. For stable heart disease, stents and bypass didn't help people live longer, even after 11 years

The study: Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in ISCHEMIA-EXTEND, JAMA, November 7, 2026

What they measured: ISCHEMIA was one of the largest trials ever to compare procedures with medication for stable heart disease. 5,179 people with stable coronary artery disease (not a recent or ongoing heart attack) and moderate-to-severe ischemia (reduced blood flow to the heart) were randomly assigned to one of two strategies. One group got medication plus routine angiography and a stent or bypass where feasible. The other got medication first, with a procedure only if medication stopped working. This study followed them for up to 13 years (median 9) to answer one question: did the procedures help people live longer?

What they found: No. At 11 years, death rates were essentially the same: 25.8% in the procedure group vs 26.9% in the medication-first group. Deaths from heart causes were slightly lower with procedures (15.8% vs 17.1%), but that difference wasn't statistically significant. Over 11 years, the procedure group gained an average of 14 days of life, a difference too small to rule out chance.

What it didn't prove: These results apply to stable disease only. The trial excluded people with a recent heart attack or unstable angina, blockages in the left main artery (the heart's most critical artery), a weak heart pump, and chest pain that couldn't be controlled. It looked at survival, not symptoms: procedures can still relieve chest pain and improve quality of life.

The takeaway: If your heart disease is stable, a stent is meant to relieve symptoms, not extend your life. Medications and lifestyle changes are foundational.


My Current Supplement Stack

  • Creatine monohydrate — I typically aim for 5 grams a day for its well-studied effects on strength and muscle when paired with resistance training. I’m also interested in the emerging research on cognition.
  • Omega-3 (EPA and DHA) — I supplement with EPA and DHA when fatty fish like salmon or sardines haven’t been a regular part of my meals.
  • Vitamin D3 + K2 — I take this especially during the winter for immunity and to support bone health.
  • Magnesium glycinate — My favorite sleep supplement on the market.
  • Berberine — to help support a healthy metabolism.

Rho offers third-party-tested liposomal delivery products. Most pills and powders lose a significant amount of their active ingredient during digestion — Rho encapsulates each nutrient in a tiny liposome that survives the gut and ferries the compound intact into the bloodstream.

Liposomal delivery helps ensure the vitamins and supplements you purchase are absorbed and not lost during digestion.

The founders, Ryan and George, firmly believe you will feel the Rho difference, but if you're not satisfied, they offer a 60-day money-back guarantee.

​If you’ve been thinking about adding Rho's liposomal supplements to your daily stack, now is the time. Their supplements are up to 45% off for the next week.​
​


Reply to this newsletter:
​
​
Did you learn from this newsletter?
What study stuck with you the most?
​
​
​
(Respond directly to this email. I read all responses)​
​
​

Only the best,

Jeremy London, MD

P.S. Don't forget to follow my podcast for free on Spotify or Apple Podcasts​

Featured in Today's Newsletter:

Before you go...

Want to read past Newsletters? Click Here​

* Disclaimer: This blog is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this blog or materials linked from this blog is at the user’s own risk. The content of this blog is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay seeking medical advice for any medical condition they may have and should consult their healthcare professionals for any such conditions.

Stay connected on all my platforms:

​Unsubscribe | Update Profile | 600 1st Ave, Ste 330 PMB 92768, Seattle, WA 98104-2246

Jeremy London, M.D.

A practicing cardiovascular surgeon shares simple steps for a longer, happier life. Join 150,000+ weekly readers

Share this page